colorectal, and lung. The term can apply to multiple types of specific therapies, including chemotherapy, radiation, hormone ...

AMAL’s lead product, ATP128, is currently being developed for stage IV colorectal cancer, a leading cause of cancer-related mortality and a significant market opportunity ($11 billion by 2025).

A recent randomized, placebo-controlled study indicates that folic acid supplementation does not lower the risk of colorectal adenomas ... be studied further. Immunotherapy for lung cancer ...

The European Commission has approved Opdivo (nivolumab) as the first-ever adjuvant immunotherapy for patients with oesophageal or gastroesophageal junction (GEJ) cancer, who have had surgery to ...

How to treat patients with stage IIB, stage IIC, and stage IIIA melanoma in the adjuvant setting is an area of controversy. Although there are some albeit limited data on this group in the BRAF/MEK ...

Not all of BMS' efforts to move its immunotherapy further up the treatment pathway have been successful. Last month, Opdivo flunked a phase 3 trial looking at its use as an adjuvant therapy for ...

The investigational arm of the trial will consider the use of immunotherapy or targeted agents, typically used for metastatic colon cancer, to potentially increase cure rates with adjuvant therapy.

The trial’s investigational arm will explore the potential of administering immunotherapy or targeted agents approved for metastatic colon cancer earlier in the disease course to ...